Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy

Seynaeve, Caroline; Verhoog, L.C.; Bosch, Lieke; Geel, Albertus N. van; Menke-Pluymers, Marian B. E.; Meijers-Heijboer, E.J.; Ouweland, Ans M.W. van den; Wagner, Anja; Creutzberg, Carien L.; Niermeijer, Martinus F.; Klijn, Jan G.M.; Brekelmans, C. T. M.

doi:10.1016/j.ejca.2004.01.017

Cited by 87 publications

(47 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overall survival rate of patients with early advanced breast cancer (BC) has increased over the years largely because adjuvant therapy, whether chemotherapy, radiotherapy or hormone therapy, has helped prevent local and distant failures (Fox, 1979;Jones and Raghavan, 1993; EBCTCG, 2005). Second malignancies that occur in long-term survivors may be due to sporadic cancers that would have occurred anyway, environmental or genetic factors (Klijn et al, 1997;Schrag et al, 1997;Turner et al, 1999;Meijers-Heijboer et al, 2000;Pierce et al, 2000Pierce et al, , 2003 StoppaLyonnet et al, 2000;Galper et al, 2002;Kauff et al, 2002;Pierce, 2002;Robson, 2002;Seynaeve et al, 2004; Kirova et al, 2005aKirova et al, , b, 2006aLaki et al, 2007), or BC treatment (Neugut et al, 1993;Inskip et al, 1994;Ahsan and Neugut, 1998;Karlsson et al, 1998;Kirova et al, 1998 Kirova et al, , 2005aKirova et al, , b, 2007Obedian et al, 2000;Rubino et al, 2000;Scholl et al, 2001;Shousha et al 2001;Yap et al, 2002 Yap et al, , 2005Deutsch et al, 2003;Zablotska and Neugut, 2003;Zablotska et al, 2005;Mellemkjaer et al, 2006) The aim of this study was to estimate the risk of a second malignancy after adjuvant treatment for BC in a homogeneous cohort of patients from a single institution. The observed incidence of second malignancies in these BC patients was compared with the expected age-adjusted number of new cases in the general population of French women as given by data from five regional registries (Remontet et al, 2003).…”

mentioning

confidence: 99%

Second malignancies after breast cancer: the impact of different treatment modalities

et al. 2008

View full text Add to dashboard Cite

Treatment for non-metastatic breast cancer (BC) may be the cause of second malignancies in long-term survivors. Our aim was to investigate whether survivors present a higher risk of malignancy than the general population according to treatment received. We analysed data for 16 705 BC survivors treated at the Curie Institute (1981 -1997) by either chemotherapy (various regimens), radiotherapy (high-energy photons from a 60 Co unit or linear accelerator) and/or hormone therapy (2 -5 years of tamoxifen). We calculated age-standardized incidence ratios (SIRs) for each malignancy, using data for the general French population from five regional registries. At a median follow-up 10.5 years, 709 patients had developed a second malignancy. The greatest increases in risk were for leukaemia (SIR: 2.07 (1.52 -2.75)), ovarian cancer (SIR: 1.6 (1.27 -2.04)) and gynaecological (cervical/endometrial) cancer (SIR: 1.6 (1.34 -1.89); Po0.0001). The SIR for gastrointestinal cancer, the most common malignancy, was 0.82 (0.70 -0.95; Po0.007). The increase in leukaemia was most strongly related to chemotherapy and that in gynaecological cancers to hormone therapy. Radiotherapy alone also had a significant, although lesser, effect on leukaemia and gynaecological cancer incidence. The increased risk of sarcomas and lung cancer was attributed to radiotherapy. No increased risk was observed for malignant melanoma, lymphoma, genitourinary, thyroid or head and neck cancer. There is a significantly increased risk of several kinds of second malignancy in women treated for BC, compared with the general population. This increase may be related to adjuvant treatment in some cases. However, the absolute risk is small. The overall survival rate of patients with early advanced breast cancer (BC) has increased over the years largely because adjuvant therapy, whether chemotherapy, radiotherapy or hormone therapy, has helped prevent local and distant failures (Fox, 1979;Jones and Raghavan, 1993; EBCTCG, 2005). Second malignancies that occur in long-term survivors may be due to sporadic cancers that would have occurred anyway, environmental or genetic factors (Klijn et al, 1997;Schrag et al, 1997;Turner et al, 1999;Meijers-Heijboer et al, 2000;Pierce et al, 2000Pierce et al, , 2003 StoppaLyonnet et al, 2000;Galper et al, 2002;Kauff et al, 2002;Pierce, 2002;Robson, 2002;Seynaeve et al, 2004; Kirova et al, 2005aKirova et al, , b, 2006aLaki et al, 2007), or BC treatment (Neugut et al, 1993;Inskip et al, 1994;Ahsan and Neugut, 1998;Karlsson et al, 1998;Kirova et al, 1998 Kirova et al, , 2005aKirova et al, , b, 2007Obedian et al, 2000;Rubino et al, 2000;Scholl et al, 2001;Shousha et al 2001;Yap et al, 2002 Yap et al, , 2005Deutsch et al, 2003;Zablotska and Neugut, 2003;Zablotska et al, 2005;Mellemkjaer et al, 2006) The aim of this study was to estimate the risk of a second malignancy after adjuvant treatment for BC in a homogeneous cohort of patients from a single institution. The observed incidence of second malignancies in these BC patients was com...

show abstract

mentioning

confidence: 99%

Second malignancies after breast cancer: the impact of different treatment modalities

et al. 2008

View full text Add to dashboard Cite

show abstract

“…[13][14][15][16] These conflicting data are a source of confusion for women with BRCA mutations and a recently diagnosed breast tumor who are choosing between the dramatically different alternatives of BCT (lumpectomy and radiation) and bilateral mastectomy. A prospective randomized trial would be optimal to determine the relative appropriateness of these strategies.…”

mentioning

confidence: 99%

Appropriateness of breast‐conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2

Robson

Svahn

McCormick

et al. 2004

Cancer

120

View full text Add to dashboard Cite

show abstract

“…But, local recurrence after breast conserving surgery in BRCA mutation carriers occurs more frequently. [8][9][10] Garcia-Etienne et al compared BRCA mutation carriers receiving breast conserving surgery and standard radio therapy with patients of sporadic breast cancer receiving the same treatment.…”

Section: Discussionmentioning

confidence: 99%

Risk Reducing Surgery in Carriers with Double Heterozygosity for BRCA1 and BRCA2 Mutations

et al. 2012

View full text Add to dashboard Cite

cancers, and family history among multiple generations. The prognosis of BRCA associated breast cancer is uncertain. It has been suggested that the prognosis is similar to that of sporadic breast cancer, while others have opined that the prognosis of BRCA asso ciated breast cancer is worse than sporadic cancer. Among the treatment options for BRCA mutation carriers, risk reducing surgery is the most effective. However, this procedure has been rarely performed in Korea. Interestingly, our case showed double heterozygosity for BRCA1 and BRCA2 mutations. The patient was diagnosed with left renal cancer and left breast cancer at 45-years-of-age, 4 years before risk reducing surgery. The patient received left radical nephrectomy and left partial mastectomy with axillary lymph node dissection. After pretest counseling, the patient underwent genetic testing that identified BRCA1 and BRCA2 mutations. After post-test counseling, the patient decided on intensive surveillance. At 49-years-of-age, the patient was newly diagnosed with contralateral breast cancer. Treatment options were discussed once again. We performed bilateral total mastectomy with immediate reconstruction and prophylactic bilateral salpingo-oophorectomy after multidisciplinary discussion. The patient has been satisfied with the results of surgery. We think this procedure is a recommendable treatment option for BRCA mutation carriers.

show abstract

Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy

Cited by 87 publications

References 32 publications

Second malignancies after breast cancer: the impact of different treatment modalities

Second malignancies after breast cancer: the impact of different treatment modalities

Appropriateness of breast‐conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2

Risk Reducing Surgery in Carriers with Double Heterozygosity for BRCA1 and BRCA2 Mutations

Contact Info

Product

Resources

About